United Therapeutics Corp (UTHR)
257.41
+2.39
(+0.94%)
USD |
NASDAQ |
May 02, 13:10
United Therapeutics Free Cash Flow: 747.60M for Dec. 31, 2023
Free Cash Flow Chart
Historical Free Cash Flow Data
| Date | Value |
|---|---|
| December 31, 2023 | 747.60M |
| September 30, 2023 | 764.30M |
| June 30, 2023 | 673.60M |
| March 31, 2023 | 722.00M |
| December 31, 2022 | 663.70M |
| September 30, 2022 | 679.00M |
| June 30, 2022 | 651.50M |
| March 31, 2022 | 673.40M |
| December 31, 2021 | 477.40M |
| September 30, 2021 | 487.30M |
| June 30, 2021 | 560.10M |
| March 31, 2021 | 574.00M |
| December 31, 2020 | 696.40M |
| September 30, 2020 | 660.30M |
| June 30, 2020 | 597.00M |
| March 31, 2020 | 563.80M |
| December 31, 2019 | -290.30M |
| September 30, 2019 | -334.50M |
| June 30, 2019 | -310.30M |
| March 31, 2019 | -296.60M |
| December 31, 2018 | 594.00M |
| September 30, 2018 | 446.80M |
| June 30, 2018 | 487.30M |
| March 31, 2018 | 410.80M |
| December 31, 2017 | 387.90M |
| Date | Value |
|---|---|
| September 30, 2017 | 655.40M |
| June 30, 2017 | 638.50M |
| March 31, 2017 | 704.00M |
| December 31, 2016 | 605.60M |
| September 30, 2016 | 445.70M |
| June 30, 2016 | 422.80M |
| March 31, 2016 | 344.70M |
| December 31, 2015 | 333.00M |
| September 30, 2015 | 427.40M |
| June 30, 2015 | 425.60M |
| March 31, 2015 | 321.08M |
| December 31, 2014 | 307.90M |
| September 30, 2014 | 310.50M |
| June 30, 2014 | 245.50M |
| March 31, 2014 | 391.82M |
| December 31, 2013 | 393.36M |
| September 30, 2013 | 386.30M |
| June 30, 2013 | 343.14M |
| March 31, 2013 | 307.88M |
| December 31, 2012 | 211.72M |
| September 30, 2012 | 180.14M |
| June 30, 2012 | 156.26M |
| March 31, 2012 | 164.50M |
| December 31, 2011 | 214.22M |
| September 30, 2011 | 195.65M |
Free Cash Flow Range, Past 5 Years
-334.50M
Minimum
Sep 2019
764.30M
Maximum
Sep 2023
487.17M
Average
651.50M
Median
Jun 2022
Free Cash Flow Benchmarks
| Liquidia Corp | -52.85M |
| Esperion Therapeutics Inc | -135.49M |
| Vertex Pharmaceuticals Inc | 3.279B |
| Heron Therapeutics Inc | -60.33M |
| Aldeyra Therapeutics Inc | -30.33M |
Free Cash Flow Related Metrics
| Cash from Operations (Quarterly) | 150.70M |
| Cash from Investing (Quarterly) | 42.10M |
| Cash from Financing (Quarterly) | -92.80M |
| Free Cash Flow Per Share (Quarterly) | 1.44 |
| Free Cash Flow to Equity (Quarterly) | 172.00M |
| Free Cash Flow to Firm (Quarterly) | 72.00M |
| Free Cash Flow Yield | 5.84% |